Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines



   small cell neuroendocrine carcinoma
  

Disease ID 1575
Disease small cell neuroendocrine carcinoma
Definition
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Synonym
[m]small cell carcinoma nos
[m]small cell carcinoma nos (morphologic abnormality)
carcinoma, oat cell
carcinoma, small cell
carcinoma, small cell [disease/finding]
carcinomas, oat cell
carcinomas, small cell
oat cell carcinoma
oat cell carcinoma (morphologic abnormality)
oat cell carcinomas
reserve cell carcinoma
round cell carcinoma
scc - small cell carcinoma
small cell cancer
small cell car. (extrapulmonary)
small cell carcinoma (disorder)
small cell carcinoma (extrapulmonary)
small cell carcinoma (morphologic abnormality)
small cell carcinoma, nos
small cell carcinomas
small cell nec
small cell neuroendocrine carcinoma (morphologic abnormality)
DOID
UMLS
C0262584
MeSH
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:5)
C0040034  |  thrombocytopenia  |  1
C0032000  |  pituitary adenoma  |  1
C0001430  |  adenoma  |  1
C0278701  |  gastric adenocarcinoma  |  1
C0001418  |  adenocarcinoma  |  1
Curated Gene
Entrez_id | Symbol | Resource(Total Genes:8)
TP53  |  7157  |  CTD_human
SMARCA4  |  6597  |  CTD_human
CYP2A6  |  1548  |  CTD_human
BIRC5  |  332  |  CTD_human
MTOR  |  2475  |  CTD_human
NPPA  |  4878  |  CTD_human
PYCARD  |  29108  |  CTD_human
UGT1A1  |  54658  |  CTD_human
Inferring Gene(Waiting for update.)
Text Mined Gene
Entrez_id | Symbol | Score | Resource(Total Genes:46)
54474  |  KRT20  |  DISEASES
1113  |  CHGA  |  DISEASES
1048  |  CEACAM5  |  DISEASES
7431  |  VIM  |  DISEASES
2026  |  ENO2  |  DISEASES
5210  |  PFKFB4  |  DISEASES
9479  |  MAPK8IP1  |  DISEASES
4656  |  MYOG  |  DISEASES
1264  |  CNN1  |  DISEASES
2922  |  GRP  |  DISEASES
5156  |  PDGFRA  |  DISEASES
6855  |  SYP  |  DISEASES
429  |  ASCL1  |  DISEASES
7157  |  TP53  |  DISEASES
3858  |  KRT10  |  DISEASES
6876  |  TAGLN  |  DISEASES
55294  |  FBXW7  |  DISEASES
6750  |  SST  |  DISEASES
3815  |  KIT  |  DISEASES
909  |  CD1A  |  DISEASES
3642  |  INSM1  |  DISEASES
354  |  KLK3  |  DISEASES
3170  |  FOXA2  |  DISEASES
4684  |  NCAM1  |  DISEASES
3579  |  CXCR2  |  DISEASES
5241  |  PGR  |  DISEASES
5454  |  POU3F2  |  DISEASES
3855  |  KRT7  |  DISEASES
23542  |  MAPK8IP2  |  DISEASES
796  |  CALCA  |  DISEASES
9899  |  SV2B  |  DISEASES
10732  |  TCFL5  |  DISEASES
23583  |  SMUG1  |  DISEASES
7080  |  NKX2-1  |  DISEASES
6752  |  SSTR2  |  DISEASES
4133  |  MAP2  |  DISEASES
5728  |  PTEN  |  DISEASES
367  |  AR  |  DISEASES
551  |  AVP  |  DISEASES
4267  |  CD99  |  DISEASES
29126  |  CD274  |  DISEASES
9058  |  SLC13A2  |  DISEASES
1029  |  CDKN2A  |  DISEASES
960  |  CD44  |  DISEASES
284111  |  SLC13A5  |  DISEASES
5378  |  PMS1  |  DISEASES
Locus(Waiting for update.)
Disease ID 1575
Disease small cell neuroendocrine carcinoma
Integrated Phenotype(Waiting for update.)
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:4)
HP:0002664  |  Neoplasia  |  2
HP:0030731  |  Carcinoma  |  1
HP:0001873  |  Low platelet count  |  1
HP:0002893  |  Pituitary adenoma  |  1
Disease ID 1575
Disease small cell neuroendocrine carcinoma
Manually Symptom(Waiting for update.)
Text Mined Symptom(Waiting for update.)
Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:10)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs121434569239112811956EGFRumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0043530012013EGFR;EGFR-AS1755181378CT
rs121434569239112815728PTENumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0008143262013EGFR;EGFR-AS1755181378CT
rs121434569239112815291PIK3CBumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0002714422013EGFR;EGFR-AS1755181378CT
rs121434569239112815290PIK3CAumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0002714422013EGFR;EGFR-AS1755181378CT
rs12143456923911281558AXLumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0002714422013EGFR;EGFR-AS1755181378CT
rs121434569239112815293PIK3CDumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0002714422013EGFR;EGFR-AS1755181378CT
rs121434569239112813480IGF1Rumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0002714422013EGFR;EGFR-AS1755181378CT
rs121434569239112815294PIK3CGumls:C0262584BeFreeAt present, secondary resistance mechanisms associated with progression are better known: clonal selection of EGFR resistance mutation (T790M mutation in exon 20), amplification of transmembrane receptors for other growth factors (c-met, HER family, IGF1R, or AXL), downstream molecular alterations in EGFR signaling pathway (PI3K or PTEN), and epithelial-mesenchymal transition or transdifferentiation to small-cell cancer.0.0002714422013EGFR;EGFR-AS1755181378CT
rs2736098247619057015TERTumls:C0262584BeFreeThe results revealed that the variant homozygote TERT rs2736098TT was associated with an increased risk of lung cancer (OR=2.017, 95%CI=1.518-2.681), especially lung adenocarcinoma (OR=2.117, 95%CI=1.557-3.043) and small cell carcinoma (OR=1.979, 95%CI: 1.174-3.334), compared with the TERT rs2736098CC genotype.0.0005428842015TERT51293971CT
rs378772824976539873CBR1umls:C0262584BeFreeAnother SNP located in CBR1 (rs3787728) also showed a significant decreased risk in SCC (OR: 0.4695% CI: 0.26-0.80, P = 0.024) and small cell carcinoma (only in current smokers) (OR: 0.06895% CI: 0.01-0.42, P = 0.028).0.0002714422014CBR1;LOC1001332862136071595TC
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:0)
(Waiting for update.)
Mapped by homologous gene(Total Items:0)
(Waiting for update.)
Chemical(Total Drugs:6)
CUI ChemicalName ChemicalID CasRN DiseaseName DiseaseID DirectEvidence PubMedIDs
C0262584arsenic trioxideC0066321327-53-3carcinoma, small cellMESH:D018288therapeutic12490120
C0262584cyclophosphamideD00352050-18-0carcinoma, small cellMESH:D018288therapeutic165045
C0262584cisplatinD00294515663-27-1carcinoma, small cellMESH:D018288therapeutic11398877
C0262584ifosfamideD0070693778-73-2carcinoma, small cellMESH:D018288therapeutic206339
C0262584vincristineD014750-carcinoma, small cellMESH:D018288therapeutic165045
C0262584vindesineD01475153643-48-4carcinoma, small cellMESH:D018288therapeutic6282107
FDA approved drug and dosage information(Total Drugs:0)
(Waiting for update.)
FDA labeling changes(Total Drugs:0)
(Waiting for update.)